Abstract
The automatic implantable defibrillator (AID-B) is designed to monitor the cardiac activity continuously, to detect malignant ventricular tachyarrhythimas, and then to deliver the countershock to restore the normal rhythm. In Feb. 1984, the first implantation of this devise in Japan was performed at NCVC. Later, another one was implanted. The risk of the implantation of the devise are small and the side effects minimal. This new therapeutic devise maybe decrease the cardiac mortality.
